

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/583,369
Filing Date	May 24, 2007
First Named Inventor	Peter R. Brink et al
Art Unit	1635
Examiner Name	Unknown TC Gibbs
Attorney Docket Number	13533/48203

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
						*

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PITTS, J. D. et al., "Premeability of Junctions Between Animal Cells. Intercellular Transfer of Nucleotides but Not of Macromolecules" Experimental Cell Research. Vol. 104 (1977) pp 153-163	
		MESNIL, M. et al., "Bystander Effect in Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Cancer Gene Therapy: role of gap-junctional intercellular communication, Database Medline [Online], Abstract, Cancer Research vol. 60:15 (August 1, 2000) pp 3989-3999	
		MESNIL, M. et al., "Bystander Killing of Cancer Cells by Herpes Simplex Virus Thymidine Kinase Gene is Medicated by Connexins" Database Biosis [Online], Abstract, Proceedings of the National Academy of Sciences of the United States of America, Vol. 93:5 (1996) pp 1831-1835	
		ZHU, W. et al., "Increased Genetic Stability of HeLa Cells after Connexin 43 Gene Transfection" Database Biosis [Online], Abstract, Cancer Research, Vol. 57:11 (1997) pp 2148-2150	
*		VALIUNAS, V. et al., "Connexin-Specific Cell-to-Cell Transfer of Short Interfering RNA by Gap Junctions", Database Biosis [Online], Abstract, J. of Physiology (Oxford), Vol. 568:2, pp 459-468	
		Supplementary European Search Report for EP 04 81 4657 mailed June 22, 2007	

\*Valiunas V. et al. was first published online 21 July 2005

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	07/21/2010
-----------------------	---------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.